As these paired Commentaries discuss, neuroscientists and architects are just beginning to collaborate, each bringing what they know about their respective fields to the task of improving the environment of research buildings and laboratories.
11 12 The BMJ has published several commentaries discussing the potential risk of pancreatitis and implications of using incretin based drugs.
Commentaries discuss vaccination for typhoid fever in Sub-Saharan Africa (Slayton, p. 903) and the effects of exercise on vaccine-induced immune responses (Edwards, p. 907).
A follow-up on this Special Focus is planned for the end of this year, with a series of commentaries discussing several articles in this issue.
Two commentaries discuss the generation of DC vaccines (Radford, p. 259) and mRNA as an off-the-shelf therapeutic (Van Lint, p. 265).
Two commentaries discuss peptide intra-tumor injection for cancer immunotherapy (Nobuoka, p. 1234), and a novel ganglioside-based vaccine as treatment for melanoma patients (Pérez, p. 1237).
The commentaries discuss the extent to which the trends and socioeconomic inequalities in cancer survival could be explained by socioeconomic differences in either individual factors or healthcare system factors.
Some commentaries discuss how insights from the clinician's practice in the treatment of individual patients can be translated to the population level, and whether recent changes in clinical practice may be expected to produce significant improvements in survival at a population level over the next 5 to 10 years.
This section also includes a review on the elimination of the latent HIV reservoir by reactivation strategies (Rasmussen, p. 790), and a number of commentaries discussing the identification of biomarkers in cancer vaccine development (Harrop, p. 800), mucosal Lactobacillus-vectored vaccines (Yu, p. 805), and short peptides as immunomodulators (Dong, p. 808).
Four commentaries discuss therapeutic vaccines as an ultimate personalized therapy (Gulley, p), the potential of nanotechnology for developing vesicle-based cancer immunotherapy (Tian, p), surrogate measures of activity for cancer-targeting vaccines (Nemunaitis, p), and peptide vaccines for hepatocellular carcinoma (Nobuoka, p).
